Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes

Cardiovascular Diabetology

Zhiguang Zhou²  Gan Huang²  Weili Tang²  Xiaoyan Chen²  Yiting Tu²  Zhaofeng Long⁴  Pengcheng Zhou¹  Aimin Xu³  Lingjiao Liu²  Yang Xiao² 

[1] Department of Medicine, the University of Hong Kong, Hong Kong, China;Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Diabetes Center, Second Xiangya Hospital, and Institute of Metabolism and Endocrinology, Central South University, Changsha, Hunan, China;Research Center of Heart, Brain, Hormone, and Healthy Aging, the University of Hong Kong, Hong Kong, China;Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha, Hunan, China

关键词: Intima-media thickness;    Subclinical atherosclerosis;    Type 2 diabetes;    Fibroblast growth factor 21;   

Others  :  1216837
DOI  :  10.1186/s12933-015-0229-9

 received in 2015-02-18, accepted in 2015-05-23,  发布年份 2015

【 摘 要 】

Background

Fibroblast growth factor 21 (FGF21), a glucose and lipid metabolic regulator, has recently been demonstrated to be associated with cardiovascular diseases (CVD) such as carotid atherosclerosis, coronary heart disease and carotid artery plaques. However, the relationship between circulating FGF21 and subclinical atherosclerosis or atherosclerosis of other arteries such as the femoral and iliac artery remains unclear. In this study, we evaluated the association of serum FGF21 with intima-media thickness (IMT) and subclinical atherosclerosis in type 2 diabetic patients.

Methods

Serum FGF21 levels were detected by enzyme-linked immunosorbent assay in 212 newly diagnosed type 2 diabetic patients without clinical symptoms of atherosclerosis or cardiovascular diseases. IMT of the carotid, femoral, and iliac arteries were measured by high-resolution B-mode ultrasound to determine the presence of subclinical atherosclerosis, which was defined as having an IMT > 1.0 mm and/or plaque on one or more of the three arteries without any clinical manifestations. The relationship between serum FGF21 levels and subclinical atherosclerosis was analyzed.

Results

Serum FGF21 levels were significantly higher in patients with subclinical atherosclerosis compared to those without [261.3 (135.1–396.4) versus 144.9 (95.9–223.0) ng/L, P < 0.001]. These differences were also observed in both men and women with subclinical atherosclerosis compared to their respective groups without [men: 243.2 (107.6–337.0) versus 136.8 (83.6–212.8) ng/L, P = 0.048; women: 292.4 (174.2–419.9) versus 160.4 (115.3–258.5) ng/L, P = 0.001]. Moreover, serum FGF21 levels showed a significantly positive correlation with carotid IMT in women (r = 0.23, P = 0.018) and with iliac IMT in both genders (women: r = 0.27, P = 0.005; men: r = 0.22, P = 0.024). Multiple logistic regression analysis further showed that serum FGF21 was an independent impact factor for subclinical atherosclerosis in patients with type 2 diabetes.

Conclusions

Serum FGF21 is elevated in newly diagnosed type 2 diabetes, and positively correlates with carotid and iliac lesions in patients with subclinical atherosclerosis, especially in women. High levels of FGF21 may be a compensatory reaction to offset atherosclerosis.

【 授权许可】

   
2015 Xiao et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011; 149(2):121-30.
• [2]Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn. 2008; 237(1):18-27.
• [3]Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT et al.. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007; 148(2):774-81.
• [4]Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al.. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115(6):1627-35.
• [5]Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D et al.. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009; 71(3):369-75.
• [6]Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F et al.. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008; 57(5):1246-53.
• [7]Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009; 32(8):1542-6.
• [8]Xiao Y, Xu A, Law LS, Chen C, Li H, Li X et al.. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab. 2012; 97(1):E54-8.
• [9]Li H, Bao Y, Xu A, Pan X, Lu J, Wu H et al.. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab. 2009; 94(6):2151-6.
• [10]Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA et al.. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010; 40(10):887-92.
• [11]Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X et al.. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010; 53(5):934-40.
• [12]Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS et al.. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010; 59(11):2781-9.
• [13]Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S et al.. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2010; 5(12):e15534.
• [14]Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M et al.. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013; 12:124. BioMed Central Full Text
• [15]Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH et al.. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013; 33(10):2454-9.
• [16]An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim HJ et al.. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract. 2012; 96(2):196-203.
• [17]Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007; 30 Suppl 1:S42-7.
• [18]Treatment of high blood cholesterol in a: executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama. 2001; 285(19):2486-97.
• [19]Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2006; 26(3):631-6.
• [20]Balbarini A, Buttitta F, Limbruno U, Petronio AS, Baglini R, Strata G et al.. Usefulness of carotid intima-media thickness measurement and peripheral B-mode ultrasound scan in the clinical screening of patients with coronary artery disease. Angiology. 2000; 51(4):269-79.
• [21]Liang J, Wang Y, Li H, Liu X, Qiu Q, Qi L. Neck circumference and early stage atherosclerosis: the cardiometabolic risk in Chinese (CRC) study. Cardiovasc Diabetol. 2014; 13:107. BioMed Central Full Text
• [22]Lukich A, Gavish D, Shargorodsky M. Normal weight diabetic patients versus obese diabetics: relation of overall and abdominal adiposity to vascular health. Cardiovasc Diabetol. 2014; 13:141. BioMed Central Full Text
• [23]Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285(19):2481-5.
• [24]Reddy RK, Mahendra J, Gurumurthy P, Jayamathi Babu S. Identification of predictable biomarkers in conjunction to Framingham risk score to predict the risk for cardiovascular disease (CVD) in Non cardiac subjects. J Clin Diagn Res. 2015; 9(2):BC23-7.
• [25]Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, Hwang TG et al.. Effects of a 3 month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf). 2011; 75(4):464-9.
• [26]Lenart-Lipinska M, Matyjaszek-Matuszek B, Gernand W, Nowakowski A, Solski J. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract. 2013; 101(2):194-200.
• [27]Liu SQ, Roberts D, Kharitonenkov A, Zhang B, Hanson SM, Li YC et al.. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep. 2013; 3:2767.
• [28]Wang XM, Song SS, Xiao H, Gao P, Li XJ, Si LY. Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells. Cell Physiol Biochem. 2014; 34(3):658-71.
• [29]Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y et al.. Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice. Circulation. 2015; 131(21):1861-71.
• [30]Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology. 2012; 153(9):4238-45.
• [31]Zhang X, Hu Y, Zeng H, Li L, Zhao J, Zhao J et al.. Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients. Cardiovasc Diabetol. 2015; 14:32. BioMed Central Full Text
• [32]Smedby O. Geometrical risk factors for atherosclerosis in the femoral artery: a longitudinal angiographic study. Ann Biomed Eng. 1998; 26(3):391-7.
• [33]Eto K, Tumenbayar B, Nagashima S, Tazoe F, Miyamoto M, Takahashi M et al.. Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract. 2010; 89(1):52-7.
• [34]Galman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstrom I et al.. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 2008; 8(2):169-74.
• [35]Tyynismaa H, Raivio T, Hakkarainen A, Ortega-Alonso A, Lundbom N, Kaprio J et al.. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab. 2011; 96(2):E351-5.